CalciMedica(CALC.US)

CalciMedica (NASDAQ:CALC) Trading Down 2.1% - Time to Sell?

CalciMedica (NASDAQ:CALC) shares fell 2.1% to $5.73, with trading volume down 51% from average levels. Analysts have mixed ratings, with one Buy and one Sell, leading to a consensus Hold rating and a price target of $16.00. The company reported a quarterly EPS of -$0.39, beating estimates. Institutional investors have increased their stakes, and CalciMedica focuses on therapies for inflammatory disorders. Despite a Hold rating, analysts suggest other stocks may be better investments.

Oppenheimer Reaffirms Their Buy Rating on CalciMedica (CALC)

Oppenheimer's Leland Gershell reaffirmed a Buy rating on CalciMedica with a $20.00 price target. The stock closed at $3.00 last Friday. Gershell, a 3-star analyst with a 2.0% average return and 39.88% success rate, focuses on Healthcare stocks. CalciMedica has a Moderate Buy consensus with a $20.00 price target.

CalciMedica | 10-Q: FY2025 Q3 Revenue: USD 0

CalciMedica reports Q3 net loss of $7.8 mln

CalciMedica reported a Q3 net loss of $7.8 million, compared to a loss of $5.6 million in the previous year. The company is in positive discussions with the FDA regarding a pivotal trial for acute pancreatitis, with trial design expected to be finalized in the first half of 2026. R&D costs increased to $3.9 million, while G&A expenses decreased to $1.8 million. Analysts maintain a "buy" rating on the stock, with a median 12-month price target of $15.50, significantly above its recent closing price of $3.21.

CalciMedica Launches Phase 2 KOURAGE Trial of Auxora in Acute Kidney Injury with Respiratory Failure

CalciMedica Inc. is currently enrolling patients in its Phase 2 KOURAGE trial for Auxora™ targeting Stage 2 or 3 acute kidney injury with respiratory failure, aiming for 150 participants and data release in early 2026. The company is also in discussions with the FDA for a pivotal trial in acute pancreatitis, with final design expected in the same timeframe. Preclinical results presented in November 2025 indicated improved kidney function in a rat model. Additionally, CalciMedica has partnered with Telperian to incorporate AI insights into the trial design.